我领导公司在肺癌方面的全球研发, 尽管近年来取得了许多进展, 仍然是世界上癌症相关死亡的最常见原因. In my role, 我与澳门葡京网赌游戏肿瘤科的肺癌团队合作,迅速推进澳门葡京赌博游戏的研究,履行澳门葡京赌博游戏治愈更多肺癌患者的承诺. 

我的肺癌研究之旅始于范德比尔特大学胸腔肿瘤学的博士后研究员. 从那时起,我一直致力于肺癌患者的研究和护理.  

我曾担任多项国家和全球肺癌免疫疗法试验的首席研究员, 针对早期和晚期发展的靶向治疗和新疗法, 并发表了150多篇论文和书籍章节. 我也是美国临床肿瘤学会(American Society of Clinical Oncology)科学委员会的活跃成员, 国际肺癌研究协会, 以及加拿大皇家内科和外科医学院.

在范德比尔特大学完成胸肿瘤学亚专业奖学金之前, 我在多伦多大学获得了医学学位, 我在那里接受内科和肿瘤学的培训, 并以优异的成绩获得理学学士学位和药理学硕士学位.

最近的研究帮助澳门葡京赌博游戏更好地了解肺癌生物学和澳门葡京赌博游戏的靶向治疗方法, immunotherapy and ADCs, 针对更多患者进行个体化治疗,解决耐药机制. 我对澳门葡京赌博游戏正在做的工作感到兴奋,澳门葡京赌博游戏正在为小细胞和非小细胞肺癌提供下一波治疗方法.

Leora Horn 全球肺癌临床主管和肺癌战略

CURRENT ROLE

全球肺癌临床主管和肺癌战略

2009-2020

Ingram Associate Professor of Cancer Research and Director of the Clinical Research Section of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center; Associate Professor of Medicine in the Division of Hematology/Oncology at the Vanderbilt University Medical Center

2009-2015

负责学院发展的助理副主席, 范德比尔特大学医学中心医学系

2008-2009

范德比尔特大学胸腔肿瘤学研究员

Featured publications

Activity and safety of nivolumab, 抗pd -1免疫检查点抑制剂, for patients with advanced, 难治性鳞状非小细胞肺癌(CheckMate 063): 2期, single-arm trial.

Activity and safety of nivolumab, 抗pd -1免疫检查点抑制剂, for patients with advanced, 难治性鳞状非小细胞肺癌(CheckMate 063): 2期, single-arm trial. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.

Pembrolizumab用于治疗非小细胞肺癌.

Pembrolizumab用于治疗非小细胞肺癌. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824.

AZD9291在EGFR抑制剂耐药非小细胞肺癌中的作用.

AZD9291在EGFR抑制剂耐药非小细胞肺癌中的作用. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.

纳武单抗与多西他赛治疗晚期非鳞状非小细胞肺癌.

纳武单抗与多西他赛治疗晚期非鳞状非小细胞肺癌. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. 纳武单抗与多西他赛治疗晚期非鳞状非小细胞肺癌. 新英格兰医学杂志373 (17):1627-39.

Nivolumab单用和Nivolumab联合ipilimumab治疗复发性小细胞肺癌(Checkmate 032), open label, phase 1/2 trial.

Nivolumab单用和Nivolumab联合ipilimumab治疗复发性小细胞肺癌(Checkmate 032), open label, phase 1/2 trial. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5.

一线纳武单抗用于IV期或复发性非小细胞肺癌.

一线纳武单抗用于IV期或复发性非小细胞肺癌. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

非小细胞肺癌切除患者联合或不联合贝伐单抗辅助化疗(E1505):开放标签, multicentre, randomised, phase 3 trial.

非小细胞肺癌切除患者联合或不联合贝伐单抗辅助化疗(E1505):开放标签, multicentre, randomised, phase 3 trial. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5.

监测治疗反应和耐药性:ALK +肺癌患者循环肿瘤DNA分析.

监测治疗反应和耐药性:ALK +肺癌患者循环肿瘤DNA分析. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. J Thorac Oncol. 2019 Nov;14(11):1901-1911. doi: 10.1016/j.jtho.2019.08.003.

http://pubmed.ncbi.nlm.nih.gov/31446141/ 

胸部恶性肿瘤患者的COVID-19 (TERAVOLT):一项国际研究的初步结果, Registry-Based, Cohort Study

胸部恶性肿瘤患者的COVID-19 (TERAVOLT):一项国际研究的初步结果, Registry-Based, Cohort Study. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; Lancet Oncol. 2020 Jul;21(7):914-922. doi: 10.1016/S1470-2045(20)30314-4.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2820%2930314-4/fulltext